Penserra Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Penserra Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,780	Closed	-$35K	–	1641
2021 Q3	$35K	Buy	1,780 +30	+2%	+$828	﹤0.01%	1152
2021 Q2	$65K	Buy	1,750 +25	+1%	+$766	﹤0.01%	932
2021 Q1	$44K	Buy	1,725 +5	+0.3%	+$128	﹤0.01%	833
2020 Q4	$37K	Buy	1,720 +1,082	+170%	+$23.8K	﹤0.01%	743
2020 Q3	$11K	Buy	+638	New	+$13.2K	﹤0.01%	810

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Penserra Capital Management's DRNA Position: Q4 2021 in Review

Penserra Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 1,780 shares — an estimated $35K sold.

Penserra Capital Management first reported a position in DRNA in Q3 2020 and held it in 5 quarters. The position peaked at $65K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Penserra Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 1,780 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $35K.
Penserra Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2020 and held it in 5 quarters.
Penserra Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $65K in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.